News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Pershing Square posted a Q3 net loss of $19.9 million.
  • Management-fee revenue rose, boosting recurring fee income.
  • Higher expenses and weaker performance fees drove the quarterly loss.
  • Pershing Square's portfolio returned 3.5% in Q3, outpacing the S&P 500.
  • The fund added seven new positions in 2026 and began building an eighth after quarter-end.
  • Prudential PLC ADS was upgraded to Buy after recent pullbacks; shares trade near $25 with a 2.13% yield.

Latest Articles

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

BillionToOne announced the publication of a real-world peer-reviewed study demonstrating that its tissue-free Northstar Response liquid biopsy assay tracks cancer treatment response as effectively or better than a commercially available tumor-informed assay, without needing tumor tissue sequencing. The study showed high concordance in measuring tum…

VERAXA Biotech Provides Overview on Implementation of  FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech AG updates on implementing New Approach Methodologies (NAMs) aligned with FDA guidelines into its R&D, enabling faster clinical progression and significantly decreasing animal testing. Utilizing advanced human-relevant models such as 3D spheroids and patient-derived xenografts, VERAXA demonstrates improved preclinical predictivity an…

Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics

Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics

Cadrenal Therapeutics has engaged Tungsten Advisors to lead a formal strategic process aimed at exploring various transactions to maximize the value of its orphan thrombo-inflammatory therapeutics portfolio. The company’s pipeline has reached significant clinical and regulatory milestones, including FDA alignment on a Phase 3 pathway for lead candi…

Rocket Lab Poised to Break Higher — A Tactical Long with Defined Risk

Rocket Lab Poised to Break Higher — A Tactical Long with Defined Risk

Rocket Lab (RKLB) is showing improving top-line momentum, bullish technicals and a low-debt balance sheet while preparing transformational M&A and product catalysts. We outline a concrete trade: entry at $74.50, target $95.00, stop loss $64.00 over a mid-term horizon (45 trading days). The trade balances upside from launch cadence, Space Systems gr…

Alpha Compute’s GAMEE Reports Q3 Record 94% YoY Growth, Reaches Monthly Profitability with over 118 million game-plays, Expands Into AI-Powered Consumer Applications

Alpha Compute’s GAMEE Reports Q3 Record 94% YoY Growth, Reaches Monthly Profitability with over 118 million game-plays, Expands Into AI-Powered Consumer Applications

Alpha Compute Corp.'s subsidiary GAMEE reported a record 94% year-over-year revenue growth in Q3 2026, reaching $1.71 million and achieving monthly profitability for the first time. The company has expanded into AI-powered consumer applications, leveraging its gaming expertise and AI capabilities, with initial AI product launches expected in Q4 202…

Eli Lilly: When Clinical Dominance Meets Valuation Pressure

Eli Lilly: When Clinical Dominance Meets Valuation Pressure

Eli Lilly has built a rare position of strength in obesity and diabetes drugs, but that dominance carries valuation risk and exposure to payor pushback and competitive launches. We outline a short trade with a clear entry, stop and target and explain the fundamental and catalyst-driven path to a meaningful pullback over the next 180 trading days.

Radware Named a Leader in 2026 IDC MarketScape for Worldwide Web Application and API Protection Platforms

Radware Named a Leader in 2026 IDC MarketScape for Worldwide Web Application and API Protection Platforms

Radware (NASDAQ: RDWR), a leader in AI and application security solutions, was named a Leader in the IDC MarketScape for Worldwide Web Application and API Protection Platforms for 2026. The company is praised for its innovative AI-based security engine and the introduction of its AI Xploit Shield, which delivers advanced, automated threat detection…

Gogoro Inc. Announces US$61.8 Million New Round of Equity Investments

Gogoro Inc. Announces US$61.8 Million New Round of Equity Investments

Gogoro Inc., a Nasdaq-listed leader in battery-swapping technology and electric mobility, announced a $61.8 million new round of equity investments from strategic investors including directors and related entities. The issuance of 24.9 million shares at $2.48 each aims to strengthen its capital base, support ongoing business development, and fulfil…

Titan Mining and U.S. Army Agree to Commercial Framework for Strategic U.S. Graphite Processing Facility

Titan Mining and U.S. Army Agree to Commercial Framework for Strategic U.S. Graphite Processing Facility

Titan Mining Corporation's subsidiary Empire State Mines has reached a commercial agreement with the U.S. Army to develop a critical minerals graphite processing facility on approximately 97 acres of Army land in Alabama. This proposed 50-year lease, with options to extend to 100 years, would enable Titan to build a domestic supply chain for value-…

Teladoc Health Expands Solo Connected Care Platform with AI-Powered Capabilities to Help Hospitals Scale Smarter Care Delivery

Teladoc Health Expands Solo Connected Care Platform with AI-Powered Capabilities to Help Hospitals Scale Smarter Care Delivery

Teladoc Health has introduced two new AI-powered features, SoloVitals and SoloScribe, within its Solo smart care platform. These innovations aim to optimize hospital workflows by enabling contactless vital sign measurements and automated clinical documentation, reducing technology fragmentation, and enhancing clinician focus on patient care. The en…

Eagle Bancorp Announces Earnings Call on October 22, 2026

Eagle Bancorp Announces Earnings Call on October 22, 2026

Eagle Bancorp, Inc., a leading community bank holding company based in Bethesda, Maryland, announced that it will hold a teleconference on October 22, 2026 to discuss its third-quarter financial results. The earnings will be released post-market on October 21, 2026. The event includes participation via webcast and is aimed at the financial communit…

International Seaways: Ride the Rally, Hedge the Reversion

International Seaways: Ride the Rally, Hedge the Reversion

International Seaways (INSW) is trading near $116 after a torrid move driven by record tanker spot rates. The company's balance sheet and cash generation are strong, but the market is pricing in persistent ultra-high rates. We lay out a tactical short trade: entry $116.42, stop $126.00, primary target $95.00 (mid-term), with a deeper target at $70 …

Buy the Dip: Why American Express' Pullback Is a High-Conviction Trade

Buy the Dip: Why American Express' Pullback Is a High-Conviction Trade

American Express has pulled back amid cyclical headwinds and investor rotation. The company’s high-margin network, affluent cardholder base, and recurring fee income make this a tactical long: enter on weakness, size for a bounce and hold for 180 trading days if fundamentals remain intact. Clear entry, stop and target are provided with risk control…